Go To Global Site
Bienvenue sur le site d’UCB en Suisse

ZILBRYSQ® is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti‑acetylcholine receptor (AChR) antibody positive.

Zilucoplan RMP Educational Materials

These essential resources contain important information to minimize the risk of meningococcal infection associated with Zilucoplan.

The patient or, if appropriate, their caregiver should be educated about treatment risks and provided with a Patient Alert Card. It is important for patients treated with Zilucoplan to always carry the Patient Alert Card with them throughout treatment and for two months after their last dose.
Please refer to the Summary of Product Characteristics for more detailed safety information about Zilucoplan.

If you have any further questions, please contact UCB-Pharma AG:
Phone: +41 (0) 58 822 31 80
E-Mail: BullePharmaMedinfo@ucb.com

IMPORTANT INFORMATION

Vaccination Confirmation

 

To minimize the risk of potential meningococcal infection with ZILBRYSQ® (Zilucoplan), ZILBRYSQ® can be dispensed only after written confirmation that the patient has received meningococcal vaccination. The supplier will not be able to process any orders for patients for whom a vaccination has not been confirmed.

Instructions on how to confirm that your patient has been vaccinated and to complete the Declaration of Vaccination are available at: https://hcp.zilucoplancap.eu/che.

Download of Zilucoplan RMP Educational Materials

German:

Information on zilucoplan and how to manage risks

Important safety information for patients and their carers

Important safety information that patients should always carry with them

Important information for dispensing pharmacists in relation to the zilucoplan controlled access program

 

French:

Information on zilucoplan and how to manage risks

Important safety information for patients and their carers

Important safety information that patients should always carry with them

Important information for dispensing pharmacists in relation to the zilucoplan controlled access program

 

Italian:

Information on zilucoplan and how to manage risks

Important safety information for patients and their carers

Important safety information that patients should always carry with them

Important information for dispensing pharmacists in relation to the zilucoplan controlled access program

Reporting of Adverse Events

Healthcare professionals should report suspected adverse reactions, especially meningococcal infections, via the ElViS portal (Electronic Vigilance System) at the following link: Reporting of adverse drug reactions for healthcare professionals (swissmedic.ch)
 

Please provide as much information as possible when reporting suspected adverse reactions, including comorbidities, past medical history, concomitant medication, and relevant timings and dates.

Alternatively, suspected side effects can be reported to UCB at: 

UCB-Pharma AG
Chem. de la Croix-Blanche 10
1630 Bulle
Switzerland
Phone: +41 (0)58 822 3180
E-Mail: 2ds.ch@ucb.com 

 

qThis medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions. Healthcare Professionals should report suspected adverse reactions via the ElViS portal (Electronic Vigilance System).

 

CH-ZL-2400062, Date of preparation: January 2025

You are about to leave www.ucbsuisse.ch.

Vous allez quitter le site français d'UCB pour accéder à un autre site du groupe. Les contraintes réglementaires et les pratiques médicales peuvent varier d'un pays à l'autre. En conséquence, les informations délivrées sur le site auquel vous allez accéder, peuvent ne pas être appropriées pour une utilisation dans votre pays.

Yes, Continue No, Cancel

You are about to leave www.ucbsuisse.ch.

Attention, vous allez quitter le site UCB Pharma France. Le lien proposé est donné à titre indicatif. Les informations que vous trouverez ne sont pas sous la responsabilité d'UCB Pharma France et peuvent ne pas être strictement conformes à la réglementation française.

Yes, Continue No, Cancel

A propos d’UCB

Durabilité

Domaines thérapeutiques

UCB Worldwide

 Search

Patients

Médicaments / Produits

Actualités

Carrières

Contact

You are about to leave www.ucbsuisse.ch.

Ce lien ouvre le site Web d'un autre fournisseur dans une nouvelle fenêtre, dont UCB Pharma GmbH n'est pas responsable du contenu.

Yes, Continue No, Cancel
© 2009 - 2022 UCB Farchim S.A., Suisse. Tous droits réservés.